GANX vs. EYEN, CASI, VYNE, UNCY, HCWB, OCUP, XLO, NXTC, LEXX, and CARA
Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Eyenovia (EYEN), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Unicycive Therapeutics (UNCY), HCW Biologics (HCWB), Ocuphire Pharma (OCUP), Xilio Therapeutics (XLO), NextCure (NXTC), Lexaria Bioscience (LEXX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.
Gain Therapeutics (NASDAQ:GANX) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
In the previous week, Gain Therapeutics had 1 more articles in the media than Eyenovia. MarketBeat recorded 17 mentions for Gain Therapeutics and 16 mentions for Eyenovia. Gain Therapeutics' average media sentiment score of 0.91 beat Eyenovia's score of 0.11 indicating that Gain Therapeutics is being referred to more favorably in the media.
Gain Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 230.74%. Eyenovia has a consensus target price of $10.00, suggesting a potential upside of 1,173.56%. Given Eyenovia's higher possible upside, analysts clearly believe Eyenovia is more favorable than Gain Therapeutics.
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 11.7% of Gain Therapeutics shares are held by insiders. Comparatively, 7.1% of Eyenovia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Gain Therapeutics has higher revenue and earnings than Eyenovia. Gain Therapeutics is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Eyenovia received 147 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 65.13% of users gave Eyenovia an outperform vote while only 62.16% of users gave Gain Therapeutics an outperform vote.
Gain Therapeutics' return on equity of -213.34% beat Eyenovia's return on equity.
Gain Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.
Summary
Eyenovia beats Gain Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Gain Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gain Therapeutics Competitors List
Related Companies and Tools
